What the MTM Documentation Generator actually produces

MEDICATION THERAPY MANAGEMENT (MTM) NOTE PATIENT DEMOGRAPHICS Date of Service: [TIMESTAMP] Encounter Type: MTM Consultation ACTIVE MEDICATION LIST 1. Metformin 1000 mg BID 2. Glipizide 10 mg BID 3. Jardiance 25 mg daily 4. Lisinopril 20 mg daily 5. Atorvastatin 40 mg QHS ALLERGIES Sulfa — rash ACTIVE MEDICAL CONDITIONS • Type 2 diabetes mellitus • Hypertension • Hyperlipidemia CLINICAL ASSESSMENT MEDICATION-RELATED PROBLEMS IDENTIFIED 1. POTENTIAL HYPOGLYCEMIA — Glipizide 10 mg BID Clinical Finding: Patient reports occasional morning dizziness; A1c improved from 8.2% to 7.1% over 6 months. Assessment: Glipizide is a [sulfonylurea — verify mechanism and cross-reactivity with sulfa allergy before prescribing adjustment]. Morning dizziness in the context of improved glycemic control may indicate hypoglycemia risk, particularly on a sulfonylurea agent. Per the prescriber's evaluation, dose reduction may be warranted to match the patient's improved metabolic status and reduce hypoglycemia incidence. Recommendation: Discuss with prescriber the option to reduce Glipizide to 5 mg BID given: (a) input-derived A1c improvement to 7.1%, and (b) patient-reported hypoglycemic symptoms. Timing and monitoring plan per prescriber's protocol. 2. DIABETES CONTROL — Multidrug Regimen Assessment Clinical Finding: Input-derived A1c 7.1% (down from 8.2%), blood pressure well-controlled (per input). Assessment: Current regimen of Metformin, Glipizide, and Jardiance is achieving stated glycemic targets. Jardiance provides [cardiorenal benefits — verify indication and appropriateness per prescriber's intent and current guideline]. Recommendation: Continue Jardiance per prescriber plan. Recheck A1c in 3 months per input guidance, or per prescriber monitoring protocol. 3. MEDICATION INTERACTION SCREENING — Potential Drug Interactions Assessment: Glipizide + Metformin: [verify current interaction severity and management in Lexicomp/Micromedex/FDA labeling]. Lisinopril + Jardiance: [verify for renal-function interaction and dose-adjustment criteria — check baseline creatinine and eGFR, not provided]. Atorvastatin: [no CYP450 inhibitors or inducers noted in current list — verify in interaction database]. Recommendation: Confirm renal function (eGFR, serum creatinine) is documented and current, particularly given Lisinopril and Metformin use. Verify prescriber is aware of glipizide + sulfa allergy relationship and has assessed cross-reactivity risk [reference current FDA or labeling guidance — verify]. PATIENT EDUCATION SUMMARY • Hypoglycemia Recognition and Management: Explained signs of low blood sugar (dizziness, shakiness, sweating, confusion) and instructed patient to check blood glucose before driving if dizziness occurs. Advised to carry fast-acting carbohydrate (glucose tablets, juice). • Medication Adherence: Reviewed importance of taking Metformin with meals and Glipizide with food to minimize GI upset and optimize absorption. Confirmed patient understanding of BID dosing. • Lifestyle: Reinforced diet and exercise modifications as supportive to glycemic and lipid targets. Advised patient to report recurring or worsening hypoglycemic symptoms to prescriber. • Follow-up Monitoring: Explained need for A1c recheck in 3 months and importance of home blood glucose monitoring per order. INTERVENTIONS 1. Provided written medication list and allergy documentation (Sulfa — rash) for patient records and prescriber coordination. 2. Recommended prescriber discussion regarding Glipizide dose reduction from 10 mg BID to 5 mg BID, pending prescriber assessment and monitoring plan. 3. Confirmed patient understanding of hypoglycemia signs and rescue protocols. 4. Arranged for follow-up MTM contact in 3 months post-A1c recheck, per facility protocol. FOLLOW-UP PLAN • 3-Month A1c Recheck: Patient to obtain A1c value per order and share with pharmacy for outcome assessment. • Prescriber Coordination: Pharmacist to document recommendation regarding Glipizide adjustment and await prescriber response. • Medication Adherence Monitoring: Assess refill patterns and patient-reported adherence at next contact. • Renal Function Verification: Confirm current eGFR and serum creatinine on file; if not current, advise prescriber to order. • Allergy Documentation: Confirm Sulfa allergy is flagged in all relevant systems (pharmacy, EHR, patient record). --- Pharmacist Name: _________________________ Date: _______________ Pharmacist Signature: _________________________________ License #: __________ Provider Notification: Recommendations communicated to [Prescriber Name / Contact Method]: ______________ Date/Time: __________

This MTM consultation reviewed a patient with Type 2 diabetes, hypertension, and hyperlipidemia on a five-drug regimen (Metformin, Glipizide, Jardiance, Lisinopril, Atorvastatin). Clinical improvement was documented with A1c reduction to 7.1% and controlled blood pressure; however, patient-reported morning dizziness prompted assessment for hypoglycemia risk related to Glipizide therapy. The pharmacist recommended discussion with the prescriber regarding a potential Glipizide dose reduction from 10 mg BID to 5 mg BID, continued Jardiance therapy for cardiorenal benefits, and 3-month A1c recheck per monitoring protocol. Medication interaction screening, renal-function verification, and sulfa-allergy documentation were flagged for prescriber confirmation.

• Coordinate with prescriber regarding Glipizide 10 mg BID → 5 mg BID dose-reduction recommendation; document prescriber response and timing of adjustment • Verify current renal function (serum creatinine, eGFR) is on file; if not current, recommend prescriber order • Confirm Sulfa allergy flag is active in pharmacy system, EHR, and patient record • Schedule follow-up MTM contact in 3 months after A1c recheck; advise patient to share lab result with pharmacy • Assess medication adherence at next contact via refill patterns and patient report • Verify interaction severity for Glipizide + Metformin and Lisinopril + Jardiance in current database (Lexicomp/Micromedex); document findings • Reinforce hypoglycemia recognition and home blood glucose monitoring with patient at each contact • Document all recommendations and prescriber communications in patient record per facility MTM documentation requirements